Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2024-01-03 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
北京市金杜律师事务所关于北京神州细胞生物技术集团股份公司2024年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and proceedings of the 2024 first extraordinary general meeting (临时股东大会) of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the legal compliance of the meeting's convening, attendance, voting procedures, and the voting results on various resolutions, including approval of a private placement of A shares and amendments to the company charter. The document is not a full annual or interim report, nor an earnings release or management discussion. It is not a proxy solicitation or a remuneration report. It is a legal opinion on the shareholder meeting and the voting results. This type of document corresponds to Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of a shareholder meeting. The document length is substantial and contains detailed voting results and legal opinions on the meeting's validity and voting outcomes, consistent with DVA filings.
2024-01-03 Chinese
神州细胞2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2024 first extraordinary shareholders meeting of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes information about the meeting date, attendance, voting results on multiple proposals related to a specific share issuance, amendments to company articles, and other corporate governance matters. The document is not a full report like an annual or interim report, nor is it a transcript or financial supplement. It is not a simple announcement of a report publication but a comprehensive disclosure of voting results and resolutions from a shareholders meeting. Therefore, it fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support a high confidence in this classification.
2024-01-03 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司首次公开发行部分限售股上市流通的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the listing and circulation of certain restricted shares of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It discusses the types of restricted shares, shareholder commitments, shareholding changes, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion. It is a formal verification opinion related to the listing of restricted shares, which aligns with a Capital/Financing Update as it concerns share issuance and capital structure changes. The document length is substantial and contains detailed information about shareholding and lock-up commitments, not just an announcement or a brief notice. Therefore, the best fitting category is Capital/Financing Update (CAP).
2023-12-22 Chinese
神州细胞首次公开发行部分限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares from the company's initial public offering (IPO). It details the number of shares becoming tradable, the lock-up periods, shareholder commitments, and regulatory approvals. The content focuses on the release of restricted shares into the market, shareholder lock-up agreements, and compliance with securities regulations. There are no financial statements, earnings data, or management discussion of financial results. The document is not a full annual or interim report, nor is it a proxy or voting result announcement. It is a formal disclosure about share circulation and shareholder commitments related to the IPO. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share listing and lock-up release, not a financial report or capital raising update per se.
2023-12-22 Chinese
神州细胞2024年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as "2024 年第一次临时股东大会会议资料" which translates to "2024 First Extraordinary General Meeting (EGM) Meeting Materials" for Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It contains detailed meeting agenda, voting procedures, and multiple proposals related to a specific capital raising event (private placement of A shares). The content includes meeting notices, agenda, proposals for shareholder approval, and related governance documents. It is clearly a set of materials prepared for a shareholders' meeting, not a report or announcement of results. The document is lengthy (15,000 characters) and contains detailed meeting materials, not just an announcement or a brief summary. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. Although it is an extraordinary meeting, the category AGM-R covers such meeting materials. Therefore, the document is best classified as AGM Information (AGM-R).
2023-12-21 Chinese
神州细胞2023年度向特定对象发行A股股票募集资金使用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度向特定对象发行A股股票募集资金使用的可行性分析报告" which translates to "2023 Feasibility Analysis Report on the Use of Funds Raised by Private Placement of A Shares." It discusses the company's plan to raise capital by issuing shares to specific investors, the necessity and feasibility of using the raised funds, and the impact on the company's financial and operational status. The content focuses on capital raising and the use of proceeds, not on financial results, audit opinions, or management changes. The document length is about 2057 characters, which is relatively short but contains substantive analysis rather than just an announcement. This fits the category of a Capital/Financing Update (CAP) rather than a simple announcement or regulatory filing. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2023-12-15 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.